Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer

Oncology Reports

Volumn 21, Issue 5, 2009, Pages 1283-1287

  Winder, Thomas ^a,b,c   Mündlein, Axel ^b,c   Rhomberg, Simone ^b,c   Dirschmid, Klaus ^b   Hartmann, Bernd L ^a   Knauer, Michael ^a,c   Drexel, Heinz ^a,b,c   Wenzl, Etienne ^a   De Vries, Alexander ^a   Lang, Alois ^a,b  

^a ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^b Vorarlberg Institute for Vascular Investigation   (Austria)

^c University of Human Sciences in the Principality of Liechtenstein   (Liechtenstein)

Author keywords

Colorectal cancer; Kirsten ras; Molecular markers; Overall survival

Indexed keywords

K RAS PROTEIN;

AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; AUSTRIA; CANCER STATISTICS; CANCER TISSUE; COLORECTAL CANCER; FEMALE; GENETIC ASSOCIATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; WILD TYPE;

AGED; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, RAS; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MUTATION; REGRESSION ANALYSIS; SURVIVAL RATE;

EID: 67649352521     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000352     Document Type: Article

References (27)

1. Boyle P and Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488, 2005.
2. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
3. Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
4. Andreyev HJ, Norman AR, Cunningham D, Oates JR and Clarke PA: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684, 1998.
5. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K and Urosevic N: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85: 692-696, 2001.
6. Bazan V, Agnese V, Corsale S, Calo V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, Tomasino RM, Colucci G, Gebbia N and Russo A: Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol 16 (Suppl 4): 50-55, 2005.
7. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ and Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297, 1987.
8. Hosaka S, Aoki Y, Akamatsu T, Nakamura N, Hosaka N and Kiyosawa K: Detection of genetic alterations in the p53 suppressor gene and the K-ras oncogene among different grades of dysplasia in patients with colorectal adenomas. Cancer 94: 219-227, 2002.
9. Kranenburg O: The KRAS oncogene: past, present, and future. Biochim Biophys Acta 1756: 81-82, 2005.
10. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD and Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
11. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P and Frebourg T: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169, 2007.
12. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F and Laurent-Puig P: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
13. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F and Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
14. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C and Rougier P: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26: S1006, 2008.
15. Al Mulla F, Milner-White EJ, Going JJ and Birnie GD: Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 187: 433- 438, 1999.
16. Al Mulla F and MacKenzie EM: Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol 195: 549-556, 2001.
17. Wittekind Ch, Meyer H-J and Bootz F: TNM Klassifikation Maligner Tumoren. Springer Verlag, pp66-70, 2003.
18. Andersen SN, Lovig T, Breivik J, Lund E, Gaudernack G, Meling GI and Rognum TO: K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 32: 62-69, 1997.
19. Benhattar J, Losi L, Chaubert P, Givel JC and Costa J: Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 104: 1044-1048, 1993.
20. Kressner U, Bjorheim J, Westring S, Wahlberg SS, Pahlman L, Glimelius B, Lindmark G, Lindblom A and Borresen-Dale AL: Ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 34: 518-521, 1998.
21. Pajkos G, Kiss I, Sandor J, Ember I and Kishazi P: The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res 20: 1695-1701, 2000.
22. Wang C, van Rijnsoever M, Grieu F, Bydder S, Elsaleh H, Joseph D, Harvey J and Iacopetta B: Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology 64: 259-265, 2003.
23. Glarakis IS, Savva S, Spandidos DA: Activation of the ras genes in malignant and premalignant colorectal tumors. Oncol Rep 5: 1451-1454, 1998.
24. Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, Zenker M, Niemeyer CM, Molven A and Shannon K: Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol 27: 7765-7770, 2007.
25. Barbacid M: Ras genes. Annu Rev Biochem 56: 779-827, 1987.
26. Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della PG and Barbacid M: Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223: 661-664, 1984.
27. Span M, Moerkerk PT, de Goeij AF and Arends JW: A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 69: 241-245, 1996.